Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Close on the heels of reporting its quarterly results, Novavax, Inc. (NASDAQ: NVAX) announced a manufacturing and supply deal with a South Korean company on Thursday.

Novavax Rallies As It Strikes New COVID-19 Vaccine Manufacturing, Supply Partnership

Shares of Novavax Inc. NVAX, -16.76% rallied 2.8% in premarket trading Thursday, after the biotechnology company said it has entered into a development and supply agreement with South Korea-based SK Group subsidiary SK Bioscience for the antigen component of Novavax's COVID-19 vaccine candidate, NVX-CoV2373.

Novavax's stock surges after supply deal with South Korea's SK Group for COVID-19 vaccine candidate

GAITHERSBURG, Md. and SEOUL, South Korea, Aug.  13, 2020  (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, and SK bioscience, a vaccine business subsidiary of SK Group, today announced a development and supply agreement for the antigen component of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate, for supply to global markets including the COVAX Facility. In addition, the companies have signed a letter of intent with the Republic of Korea’s Ministry of Health and Welfare to work toward broad and equitable access to NVX-CoV2373 for the global market as well as to make the vaccine available in South Korea.

Novavax and SK bioscience Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate

Home Depot

Penn Entertainment

Rosetta Stone

Home Depot, Novavax, Rosetta Stone and Penn National Gaming were our top stock trades for Thursday. That said, let's look at the charts now.

4 Top Stock Trades for Thursday: HD, NVAX, RST, PENN

Novavax (NVAX) news for Thursday concerning includes the company's stock falling hard on talk of a vaccine for the novel coronavirus.
The post Novavax News: Why NVAX Stock Is Plunging 16% Today appeared first on InvestorPlace.

Novavax News: Why NVAX Stock Is Plunging 16% Today

Novavax looks like a winner with its positive Covid-19 vaccine results. NVAX stock is worth at least 35% more than today based on widespread acceptance of its vaccine.

Novavax Looks Like a Winner With Its Vaccine Results

Sorrento Therapeutics Inc

Vaxart

Major new developments in the race for a COVID-19 vaccine are driving investors to reevaluate their positions.

Why Novavax, Vaxart, Sorrento Therapeutics, and Other Coronavirus Stocks Plummeted Today

Moderna

BioNTech SE

A shocking announcement out of Russia sent shares of companies working on COVID-19 vaccines and treatments sharply lower.

Why Sorrento Therapeutics, Novavax, Moderna, and Other Coronavirus Stocks Plunged Today

Inovio Pharmaceuticals

What looked like another rotation day turned into something more negative.

Stock Markets Take Late-Day Hit; Inovio, Novavax Plunge on Coronavirus Vaccine Concerns

Government backing has helped the tiny biotech ramp up quickly.

Novavax Ready to Produce Nearly 3 Billion Coronavirus Vaccine Doses (With a Little Help From Friends)

Novavax's (NVAX) loss narrows for the second quarter of 2020 but revenues miss the mark.

Novavax's (NVAX) Earnings Beat in Q2, Sales Lag Estimates

Novavax, Inc. (NASDAQ: NVAX) released better-than-expected bottom-line results for the second quarter Monday, although revenue trailed estimates.

After Mixed Q2 Report, Novavax Analyst Details Possible Coronavirus Vaccine Catalysts

The small-cap biotech has emerged as one of the favorites in the race for a COVID-19 vaccine.

Why in the World Is Novavax Stock Up 4,000%?

Novavax, Inc. (NVAX) CEO Stan Erck on Q2 2020 Results - Earnings Call Transcript

JPMorgan Chase & Co

"I'm always searching for a mantra for any given market, and I think I've found it for this one," the "Mad Money" host said.

Jim Cramer debuts new mantra: 'No news is good news'

AstraZeneca

Merck

Pfizer

COVID-19 has weakened the US economy more than China's.

T Cell Responses To Coronavirus Vaccines Are In The Interest Of National Security

SEATTLE, Aug. 10, 2020 /PRNewswire/ -- AGC Biologics, a global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced it has expanded its partnership with Novavax, Inc.

AGC Biologics Expands Partnership with Novavax

GAITHERSBURG, Md., Aug.  10, 2020  (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced its financial results and operational highlights for the second quarter ended June 30, 2020.

Novavax Reports Second Quarter 2020 Financial and Operational Results

Eli Lilly

Two big drugmakers and one small biotech appear to be great picks right now.

3 Top Coronavirus Stocks to Buy in August

Takeda Pharmaceutical

Global expansion is here for the vaccine that's months away from a regulatory approval.

Novavax Partners With Takeda to Sell Its Coronavirus Vaccine in Japan

Is  (NVAX) Outperforming Other Medical Stocks This Year?

Is Novavax (NVAX) Stock Outpacing Its Medical Peers This Year?

Amicus Therapeutics

Halozyme Therapeutics

Intercept Pharma

Reata Pharmaceuticals

Let us take a look at five small biotech companies, NVAX, ICPT, FOLD, RETA, HALO, which are gearing up for their earnings release.

Biotech Stock Q2 Earnings on Aug 10: NVAX, ICPT & More

Following strong clinical data from its COVID-19 vaccine, shares of Novavax are trading at record highs.

Is Now the Right Time to Buy Novavax Stock?

Kopin

QuidelOrtho Corp

Unum Therapeutics

Veritone

On Aug 6, the Nasdaq Composite Index topped the milestone of 11,000. The tech-heavy laden completed its 1000-point journey in 40 trading days, representing the fastest ever rise in 20 years.

Nasdaq Tops 11,000: 5 Best Stocks With Room for More Upside

GAITHERSBURG, Md. and OSAKA, Japan, Aug.  07, 2020  (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK), today announced a partnership for the development, manufacturing and commercialization of NVX‑CoV2373, Novavax’ COVID‑19 vaccine candidate, in Japan. NVX‑CoV2373 is a stable, prefusion protein made using Novavax’ recombinant protein nanoparticle technology and includes Novavax’ proprietary Matrix‑M™ adjuvant. Takeda will receive funding from the Government of Japan’s Ministry of Health, Labour and Welfare (MHLW) to support the technology transfer, establishment of infrastructure and scale-up of manufacturing. Takeda anticipates the capacity to manufacture over 250 million doses of the COVID-19 vaccine per year1.

News for Novavax Stock (NVAX)